Gamma Knife Controls Craniopharyngioma but Symptom-Driven Interventions Remain Common

Craniopharyngiomas are histologically benign but clinically aggressive epithelial tumors that frequently adhere to critical neurovascular structures, making complete surgical resection difficult [1, 2, 3]. Despite high survival rates, patients often face significant long-term morbidity from panhypopituitarism (the inadequate production of all anterior pituitary hormones), visual deficits, and hypothalamic dysfunction (damage to the brain region regulating appetite, temperature, and sleep) [2, 3]. Gamma Knife radiosurgery has emerged as a standard adjuvant or salvage therapy for residual and recurrent disease, with meta-analytic data demonstrating a five-year progression-free survival (the period during and after treatment where the tumor does not grow) of 70% (95% CI: 64-76%) [4, 5]. However, long-term efficacy data remain sparse because these tumors can recur decades after initial treatment; for instance, a nationwide cohort with a mean follow-up of 21 years found that the progression-free survival rate drops to 40% at 30 years [6, 7]. A new retrospective study of 72 patients now provides critical long-term data on radiographic control and identifies a gross tumor volume (the total visible extent of the tumor on imaging) of less than 2.0 cubic centimeters as a predictor of superior treatment success [8].